Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Nasdaq100 ETF (QQQ) Price & Performance

Abeona Therapeutics IncTrade
Nasdaq100 ETFTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Nasdaq100 ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Nasdaq100 ETF trades at $722.07. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Nasdaq100 ETF nearer its low. Which is the better fit depends on your goals.

ABEOQQQ
Market Cap
$421.19M
Sector
Health
52-Week High
$7.45$746.16
52-Week Low
$4.17$558.34
Enterprise Value
$276.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

Nasdaq100 ETF

QQQ trades at $723.65, up 0.39% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF's momentum is supported by positive market breadth and tech earnings beats, though RSI levels suggest some near-term overbought conditions. A dividend of $0.81 per share is scheduled for July 2026.

Outlook remains positive given strong tech sector performance and institutional inflows, but risks include high valuation sensitivity and market volatility. Analyst sentiment is split evenly between buy and sell recommendations, reflecting uncertainty over sustained growth versus potential pullbacks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Nasdaq100 ETF

The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on QQQ